Monographie - Deferoxamine mesylate - Stabilis 4.0

Last update :
19/11/2024

Chelator

Deferoxamine mesylate

injection

Stability in solutions

Stability of mixtures

Factors which affect stability

Compatibility

Route of administration

References

pdf

Chemical structure

Tradename

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Deferoxamina	Spain
Deferoxamine mesylate	Canada, United States of America
Deferoxaminmesilat	Germany
Desferal	Argentina, Australia, Austria, Belgium, Canada, Chile, Colombia, Denmark, Egypt, Finland, France, Germany, Great Britain, Greece, Hungary, Iceland, India, Iran, Ireland, Italy, Luxembourg, Malaysia, Mexico, Morocco, Netherlands, Norway, Poland, Portugal, Romania, Saudi Arabia, Sweden, Switzerland, Tunisia, Turkey, United States of America, Venezuela
Desferin	Denmark, Spain
Desferioxamine mesilate	Great Britain
Desfonak	Iran
PMS desferoxamine	Canada
Talifer	Mexico

References

injection

References : Deferoxamine mesylate

	Type	Publication
5	Journal	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
960	Journal	Koren G, Tesoro A, Leeder JS, Bentur Y, Olivieri N. Stability of aqueous solutions of deferoxamine. Can J Hosp Pharm 1990 ; 43: 57-60.
1669	Journal	Hayes DM, Reilly RM, Lee MMC. The pharmaceutical stability of deferoxamine mesylate. Can J Hosp Pharm 1994 ; 47: 9-14.
2156	Journal	Kane MP, Bailie GR, Moon DG, Siu I. Stability of deferoxamine peritoneal dialysate solutions. Perit Dial Int 1994 ; 14: 396-398.
3671	Manufacturer	Deferoxamine - Résumé des caractéristiques du produit Teva UK Ltd 2016
3728	Journal	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.

Mentions Légales